Speaking to ecancer from the Academy for Cancer Education (ACE) 3rd Asia Pacific Prostate Cancer Conference (APPCC) in Shanghai, Prof Paul de Souza from the University of Western Sydney, Australia, interviews Dr Wayne Yen-Hwa Chang from the Taipei Veterans General Hospital in Taiwan.
Dr Chang begins by defining clinical progression in metastatic castration-resistant prostate cancer (mCRPC), noting how much weight he places on PSA progression within this definition. He emphasises the importance of early identification of progression, and of early management. He goes on to outline the role of biomarkers in assessing disease progression and guiding treatment choice.
Dr Chang notes how mCRPC is managed in Taiwan with the drugs available, and emphasises the importance of enrolling patients into clinical trials. Dr Chang then comments on how he thinks treatment will change in the coming years in Taiwan, and the cost-effectiveness of therapy.
This video is sponsored by an educational grant from Janssen Asia Pacific, pharmaceutical companies of Johnson & Johnson